Targeting PAR4 to Reduce Atherosclerosis.
作者信息
Barrett Tessa J
机构信息
New York University Grossman School of Medicine, Department of Medicine, Department of Pathology, New York.
出版信息
Arterioscler Thromb Vasc Biol. 2023 Nov;43(11):2179-2182. doi: 10.1161/ATVBAHA.123.320046. Epub 2023 Sep 28.
Abstract
摘要
相似文献
1
Targeting PAR4 to Reduce Atherosclerosis.靶向PAR4以减轻动脉粥样硬化。
Arterioscler Thromb Vasc Biol. 2023 Nov;43(11):2179-2182. doi: 10.1161/ATVBAHA.123.320046. Epub 2023 Sep 28.
2
PAR4 Inhibition Reduces Coronary Artery Atherosclerosis and Myocardial Fibrosis in SR-B1/LDLR Double Knockout Mice.PAR4 抑制减少了载脂蛋白 B 受体 1/低密度脂蛋白受体双重基因敲除小鼠的冠状动脉粥样硬化和心肌纤维化。
Arterioscler Thromb Vasc Biol. 2023 Nov;43(11):2165-2178. doi: 10.1161/ATVBAHA.123.319767. Epub 2023 Sep 7.
3
Structure-function analysis of protease-activated receptor 4 tethered ligand peptides. Determinants of specificity and utility in assays of receptor function.蛋白酶激活受体4拴系配体肽的结构-功能分析。受体功能测定中特异性和实用性的决定因素。
J Biol Chem. 2000 Jun 30;275(26):19728-34. doi: 10.1074/jbc.M909960199.
4
Protease-activated receptor (PAR) 1 and PAR4 differentially regulate factor V expression from human platelets.蛋白酶激活受体（PAR）1 和 PAR4 可调节人血小板中因子 V 的表达。
Mol Pharmacol. 2013 Apr;83(4):781-92. doi: 10.1124/mol.112.083477. Epub 2013 Jan 10.
5
Thrombin-induced reactive oxygen species generation in platelets: A novel role for protease-activated receptor 4 and GPIbα.凝血酶诱导血小板中活性氧的产生：蛋白酶激活受体4和糖蛋白Ibα的新作用。
Redox Biol. 2015 Dec;6:640-647. doi: 10.1016/j.redox.2015.10.009. Epub 2015 Oct 28.
6
Role of protease-activated receptor 4 in mouse models of acute and chronic kidney injury.蛋白酶激活受体 4 在急性和慢性肾损伤小鼠模型中的作用。
Am J Physiol Renal Physiol. 2024 Feb 1;326(2):F219-F226. doi: 10.1152/ajprenal.00162.2023. Epub 2023 Nov 30.
7
Macrophage Migration Inhibitory Factor Mediates PAR-Induced Bladder Pain.巨噬细胞移动抑制因子介导蛋白酶激活受体诱导的膀胱疼痛。
PLoS One. 2015 May 28;10(5):e0127628. doi: 10.1371/journal.pone.0127628. eCollection 2015.
8
Biphasic kinetics of activation and signaling for PAR1 and PAR4 thrombin receptors in platelets.血小板中PAR1和PAR4凝血酶受体激活及信号传导的双相动力学
Biochemistry. 2000 May 9;39(18):5458-67. doi: 10.1021/bi9927078.
9
PAR1 antagonists inhibit thrombin-induced platelet activation whilst leaving the PAR4-mediated response intact.蛋白酶激活受体1（PAR1）拮抗剂可抑制凝血酶诱导的血小板活化，而使PAR4介导的反应保持完整。
Platelets. 2015;26(3):236-42. doi: 10.3109/09537104.2014.902924. Epub 2014 Apr 21.
10
Vascular protease-activated receptor 4 upregulation, increased platelet aggregation, and coronary lipid deposits induced by long-term dabigatran administration - results from a diabetes animal model.长期达比加群酯给药引起的血管蛋白酶激活受体 4 上调、血小板聚集增加和冠状动脉脂质沉积-来自糖尿病动物模型的结果。
J Thromb Haemost. 2019 Mar;17(3):538-550. doi: 10.1111/jth.14386. Epub 2019 Feb 6.
本文引用的文献
1
PAR4 Inhibition Reduces Coronary Artery Atherosclerosis and Myocardial Fibrosis in SR-B1/LDLR Double Knockout Mice.PAR4 抑制减少了载脂蛋白 B 受体 1/低密度脂蛋白受体双重基因敲除小鼠的冠状动脉粥样硬化和心肌纤维化。
Arterioscler Thromb Vasc Biol. 2023 Nov;43(11):2165-2178. doi: 10.1161/ATVBAHA.123.319767. Epub 2023 Sep 7.
2
The predominant PAR4 variant in individuals of African ancestry worsens murine and human stroke outcomes.非洲裔个体中主要的 PAR4 变体可使鼠类和人类的中风预后恶化。
J Clin Invest. 2023 Sep 15;133(18):e169608. doi: 10.1172/JCI169608.
3
Aspirin for the Primary Prevention of Cardiovascular Disease: Time for a Platelet-Guided Approach.阿司匹林用于心血管疾病一级预防：是时候采用血小板指导的方法了。
Arterioscler Thromb Vasc Biol. 2022 Oct;42(10):1207-1216. doi: 10.1161/ATVBAHA.122.318020. Epub 2022 Sep 1.
4
Genetic deletion of platelet PAR4 results in reduced thrombosis and impaired hemostatic plug stability.血小板 PAR4 的基因缺失可导致血栓形成减少和止血栓稳定性受损。
J Thromb Haemost. 2022 Feb;20(2):422-433. doi: 10.1111/jth.15569. Epub 2021 Nov 10.
5
Using PAR4 Inhibition as an Anti-Thrombotic Approach: Why, How, and When?使用 PAR4 抑制作为抗血栓形成的方法：为什么、如何以及何时？
Int J Mol Sci. 2019 Nov 11;20(22):5629. doi: 10.3390/ijms20225629.
6
Protease-activated receptor 4 activity promotes platelet granule release and platelet-leukocyte interactions.蛋白酶激活受体 4 的活性促进血小板颗粒释放和血小板-白细胞相互作用。
Platelets. 2019;30(1):126-135. doi: 10.1080/09537104.2017.1406076. Epub 2018 Dec 18.
7
A function-blocking PAR4 antibody is markedly antithrombotic in the face of a hyperreactive PAR4 variant.一种针对 PAR4 的功能阻断抗体在面对高反应性 PAR4 变体时具有显著的抗血栓作用。
Blood Adv. 2018 Jun 12;2(11):1283-1293. doi: 10.1182/bloodadvances.2017015552.
8
Dabigatran reduces thrombin-induced platelet aggregation and activation in a dose-dependent manner.达比加群以剂量依赖的方式降低凝血酶诱导的血小板聚集和活化。
J Thromb Thrombolysis. 2017 Aug;44(2):216-222. doi: 10.1007/s11239-017-1512-2.
9
Blockade of protease-activated receptor-4 (PAR4) provides robust antithrombotic activity with low bleeding.阻断蛋白酶激活受体 4（PAR4）可提供强大的抗血栓活性，同时出血风险低。
Sci Transl Med. 2017 Jan 4;9(371). doi: 10.1126/scitranslmed.aaf5294.
10
Protease-activated receptors in hemostasis.止血过程中的蛋白酶激活受体。
Blood. 2016 Jul 14;128(2):169-77. doi: 10.1182/blood-2015-11-636472. Epub 2016 Apr 28.
Zotero 插件